Fulcrum Therapeutics announces FDA lifts clinical hold on FTX-6058 IND for sickle cell disease

Fulcrum Therapeutics, Inc.

FDA lifted clinical hold on Fulcrum's IND for FTX-6058 on August 22, 2023.
FTX-6058 is a potential treatment for sickle cell disease.
Fulcrum posted a presentation with amended protocol and planned Phase 1b trial details.
Clinical development can now resume; no financial terms disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.